Back to Search
TARUN KEWALRAMANI, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1538130570IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
155424(MA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
NORTHWESTERN UNIVERSITY FEINBERG MEDICAL SCHOOL
Class of 1995
Research & Publications (20)
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
PMID 16759221·Br J Haematol·2006
8-other
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
PMID 13130314·Bone Marrow Transplant·2003
8-other
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
PMID 19438504·Br J Haematol·2009
8-other
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
PMID 19018081·J Clin Oncol·2009
8-other
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
PMID 18574442·Bone Marrow Transplant·2008
8-other
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
PMID 18458821·J Neurooncol·2008
3-trial
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
PMID 18332466·J Clin Oncol·2008
3-trial
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
PMID 17897298·Br J Haematol·2007
3-trial
The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation.
PMID 16923608·Cytotherapy·2006
8-other
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
PMID 16398649·Br J Haematol·2006
3-trial
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
PMID 16319952·Leukemia·2006
3-trial
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.
PMID 16091454·Blood·2005
3-trial
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
PMID 15640822·Bone Marrow Transplant·2005
3-trial
Palifermin for oral mucositis after intensive therapy for hematologic cancers.
PMID 15602019·N Engl J Med·2004
3-trial
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.
PMID 14871252·Br J Haematol·2004
8-other
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
PMID 14739217·Blood·2004
3-trial
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
PMID 12875607·Cancer Immun·2003
8-other
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
PMID 12736224·Ann Oncol·2003
6-review
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
PMID 12676776·Blood·2003
3-trial
Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
PMID 11296139·Curr Oncol Rep·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 41 MALL RD
BURLINGTON, MA 01805 - Phone
- (781) 744-8400
Quick Facts
- NPI
- 1538130570
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile